Health-related quality of life and symptom burden in patients with melanoma during and after immune checkpoint inhibitor therapy – a pilot study
Needs of patients during and after ICI therapy appear to differ with an assumed remaining symptom burden in survivors of melanoma. For measuring HRQoL a therapy-/disease-specific instrument should be considered. Rising numbers of patients undergoing ICI therapy and survivors underscore the need for comprehensive data on HRQoL and specific aspects of treatment.
Authors
- Olaf Schoffer (ORCID: https://orcid.org/0000-0001-6922-7148)
- Friedegund Meier (ORCID: https://orcid.org/0000-0003-4340-9706)
- Martin Eichler (ORCID: https://orcid.org/0000-0001-9654-2207)
- Jochen Schmitt (ORCID: https://orcid.org/0000-0003-0264-0960)
- Frank Friedrich Gellrich (ORCID: https://orcid.org/0000-0002-2164-4644)
- Lea Pöschmann
Institutions
- National Center for Tumor Diseases (DE)
- University Hospital Carl Gustav Carus (DE)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-10-16
- DOI
- https://doi.org/10.1186/s12885-025-15069-w
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09